Animal Research: Reporting <i>In Vivo</i> Experiments: The ARRIVE Guidelines

Kilkenny, Carol; Browne, William J.; Cuthill, Innes C.; Emerson, Michael; Altman, Douglas G.

doi:10.1002/jgm.1473

Cited by 1,674 publications

(1,664 citation statements)

References 2 publications

Supporting

Mentioning

1,647

Contrasting

Unclassified

Order By: Relevance

“…This assumes that the level of current research is inadequate and researchers must improve research study design, data handling, and interpretation. This recommendation is consistent with previous recommendations and publications, including STAIR [20], RIGOR [21][22][23][24] and CAMARADES [25,26], guidelines that are now mainstays in the field. However, based upon manuscript submission to this Journal, there is still less than 30% compliance by research laboratories worldwide primarily because high quality fully transparent research can be costly and there is insufficient funding available (see [30]).…”

Section: Proceedings From the Workhopsupporting

confidence: 88%

Translational Stroke Research Opportunities and a Strategy to Develop Effective Cytoprotection

Lapchak

2017

Transl. Stroke Res.

View full text Add to dashboard Cite

Section: Proceedings From the Workhopsupporting

confidence: 88%

Translational Stroke Research Opportunities and a Strategy to Develop Effective Cytoprotection

Lapchak

2017

Transl. Stroke Res.

View full text Add to dashboard Cite

“…All animal care and experimental procedures were conducted in accordance with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals and approved by Wake Forest University's Institutional Animal Care and Use Committee. This study is reported in accordance with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines for reporting experiments involving animals (60). Twelve adult male and female rhesus monkeys (Macaca mulatta), age 10-17 y and weight 6.5-13 kg, were kept at an indoor facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.…”

Section: Methodsmentioning

confidence: 99%

A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates

Ding

Czoty

Kiguchi

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

102

View full text Add to dashboard Cite

Despite the critical need, no previous research has substantiated safe opioid analgesics without abuse liability in primates. Recent advances in medicinal chemistry have led to the development of ligands with mixed mu opioid peptide (MOP)/nociceptin-orphanin FQ peptide (NOP) receptor agonist activity to achieve this objective. BU08028 is a novel orvinol analog that displays a similar binding profile to buprenorphine with improved affinity and efficacy at NOP receptors. The aim of this preclinical study was to establish the functional profile of BU08028 in monkeys using clinically used MOP receptor agonists for side-by-side comparisons in various wellhoned behavioral and physiological assays. Systemic BU08028 (0.001-0.01 mg/kg) produced potent long-lasting (i.e., >24 h) antinociceptive and antiallodynic effects, which were blocked by MOP or NOP receptor antagonists. More importantly, the reinforcing strength of BU08028 was significantly lower than that of cocaine, remifentanil, or buprenorphine in monkeys responding under a progressive-ratio schedule of drug self-administration. Unlike MOP receptor agonists, BU08028 at antinociceptive doses and ∼10-to 30-fold higher doses did not cause respiratory depression or cardiovascular adverse events as measured by telemetry devices. After repeated administration, the monkeys developed acute physical dependence on morphine, as manifested by precipitated withdrawal signs, such as increased respiratory rate, heart rate, and blood pressure. In contrast, monkeys did not show physical dependence on BU08028. These in vivo findings in primates not only document the efficacy and tolerability profile of bifunctional MOP/NOP receptor agonists, but also provide a means of translating such ligands into therapies as safe and potentially abusefree opioid analgesics.N/OFQ peptide receptor | respiratory depression | reinforcing effects | physical dependence | mu opioid peptide receptor P ain, a symptom of numerous clinical disorders, afflicts millions of people worldwide. Despite the remarkable advances in the identification of potential targets as analgesics in the last decade, mu opioid peptide (MOP) receptor agonists remain the most widely used analgesics for pain management (1). Several side effects associated with MOP receptor agonists have severely limited the value of opioid analgesics, however (2). Owing to the abuse liability and the high mortality rate caused by respiratory arrest, opioid abuse not only has dire consequences, but also leads to mounting medical and economic burdens in our society (3-5). There is a clear, unmet need for safe analgesics without abuse liability in the global community.Buprenorphine, a partial MOP receptor agonist, is considered a safe analgesic because of its ceiling effect on respiratory depression (6, 7). Buprenorphine is commonly used in both human and veterinary medicine to treat various pain conditions, including cancer pain and neuropathic pain (7,8). However, buprenorphine is not devoid of reinforcing effects, the most devastating side effect...

show abstract

“…All studies were conducted in accordance with the principles and procedures outlined as "3Rs" in the guidelines of EU (86/609/EEC), FELASA, and the National Centre for the 3Rs (the ARRIVE; Kilkenny et al, 2010), and were approved by the Animal Care Committee of the Center for…”

Section: Subjectsmentioning

confidence: 99%

Presynaptic TRPV1 vanilloid receptor function is age- but not CB1 cannabinoid receptor-dependent in the rodent forebrain

Köles

Garção

Zádori

et al. 2013

Brain Research Bulletin

View full text Add to dashboard Cite

Neocortical and striatal TRPV1 (vanilloid or capsaicin) receptors (TRPV1Rs) are excitatory ligand-gated ion channels, and are implicated in psychiatric disorders. However, the purported presynaptic neuromodulator role of TRPV1Rs in glutamatergic, serotonergic or dopaminergic terminals of the rodent forebrain remains little understood. With the help of patch-clamp electrophysiology and neurochemical approaches, we mapped the age-dependence of presynaptic TRPV1R function, and furthermore, we aimed at exploring whether the presence of CB1 cannabinoid receptors (CB1Rs) influences the function of the TRPV1Rs, as both receptor types share endogenous ligands. We found that the major factor which affects presynaptic TRPV1R function is age: by post-natal day 13, the amplitude of capsaicin-induced release of dopamine and glutamate is halved in the rat striatum, and two weeks later, capsaicin already loses its effect. However, TRPV1R receptor function is not enhanced by chemical or genetic ablation of the CB1Rs in dopaminergic, glutamatergic and serotonergic terminals of the mouse brain. Altogether, our data indicate a possible neurodevelopmental role for presynaptic TRPV1Rs in the rodent brain, but we found no cross-talk between TRPV1Rs and CB1Rs in the same nerve terminal. AbstractNeocortical and striatal TRPV 1 (vanilloid or capsaicin) receptors (TRPV 1 Rs) are excitatory ligandgated ion channels, and are implicated in psychiatric disorders. However, the purported presynaptic neuromodulator role of TRPV 1 Rs in glutamatergic, serotonergic or dopaminergic terminals of the rodent forebrain remains little understood. With the help of patch-clamp electrophysiology and neurochemical approaches, we mapped the age-dependence of presynaptic TRPV 1 R function, and furthermore, we aimed at exploring whether the presence of CB 1 cannabinoid receptors (CB 1 Rs) influences the function of the TRPV 1 Rs, as both receptor types share endogenous ligands.We found that the major factor which affects presynaptic TRPV 1 R function is age: by post-natal day 13, the amplitude of capsaicin-induced release of dopamine and glutamate is halved in the rat striatum, and two weeks later, capsaicin already loses its effect. However, TRPV 1 R receptor function is not enhanced by chemical or genetic ablation of the CB 1 Rs in dopaminergic, glutamatergic and serotonergic terminals of the mouse brain.Altogether, our data indicate a possible neurodevelopmental role for presynaptic TRPV 1 Rs in the rodent brain, but we found no cross-talk between TRPV 1 Rs and CB 1 Rs in the same nerve terminal.

show abstract

Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines

Cited by 1,674 publications

References 2 publications

Translational Stroke Research Opportunities and a Strategy to Develop Effective Cytoprotection

Translational Stroke Research Opportunities and a Strategy to Develop Effective Cytoprotection

A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates

Presynaptic TRPV1 vanilloid receptor function is age- but not CB1 cannabinoid receptor-dependent in the rodent forebrain

Contact Info

Product

Resources

About